A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Denosumab (Primary)
- Indications Corticosteroid-induced osteoporosis
- Focus Therapeutic Use
- Sponsors Amgen
- 17 Jul 2017 Planned initiation date changed from 30 Jun 2017 to 15 Sep 2017.
- 05 Jun 2017 Planned initiation date changed from 31 May 2017 to 30 Jun 2017.
- 18 Jan 2017 New trial record